Device Trial Radar · NCT06806332
Glaucoma Drop Aids Part 2
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Boston Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boston Medical Center Patient Safety Grant
- First posted
- Feb 4, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Glaucoma medications are vital to disease management and prevention of further loss of vision as over time glaucoma will lead to irreversible blindness. The average size of a glaucoma medication bottle is around 10cc and these medications when used 2-3 times daily are expected to last patients an entire month. The investigators found that at Boston Medical Center (BMC) a majority of Yawkey Eye Clinic patients are unable to deliver the drops into their eyes due to poor vision or difficulty squeezing drop bottles. These patients also often deliver more than a necessary amount leading to premature completion of the bottle. However, because the cost benefit ratio of these drop aids is unclear, they are not routinely offered to the patients. Although the efficacy of these drop aids has not been well studied, if effective, the cost of these drop aids would more than pay themselves by improving medication compliance and visual function of the patients. This study aims to determine the efficacy of the Nanodropper in the BMC Yawkey Eye Clinic patient population.
Conditions
- Glaucoma
- Intraocular Pressure
Interventions
NanodropperDevice
The Nanodropper is the only FDA-listed, volume-reducing adaptor for eyedrop bottles. By twisting the Nanodropper onto a compatible bottle, the drop-size can be reduced by over 60%. Smaller drops have been shown to reduce waste, cost, and side effects.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Completion of topical ophthalmic drug bottleTime frame: 12 weeks
- Satisfaction with dispensing opthalmic medicationTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yawkey Eye Clinic, Boston Medical Center
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.